ASH 2015 - Multiple Myeloma

Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Patient Preferences on Treatment Attributes in MM

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Lenalidomide/Dexamethasone versus Bortezomib/Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma: Results of the Phase 3 SWOG S0777 Trial

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Randomized Phase 2 Study of the All-Oral Combination of Ixazomib plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—3-Year Safety and Efficacy Follow-Up

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Page 1 of 3

1
2
3